KIADIS PHARMA RAISES €5 MILLION IN PRIVATE PLACEMENT WITH INSTITUTIONAL INVESTORS

Amsterdam, The Netherlands, June 13, 2017 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Euronext Brussels: KDS), a clinical stage biopharmaceutical company developing innovative products to make bone marrow transplantations for patients suffering from blood cancers and inherited blood disorders safer and more effective, today announces that it has raised €5 million in gross proceeds through a private placement (the “Transaction”) of new shares (the “New Shares”) completed prior to the open of the market today.
The Company has placed 746,269 New Shares with a small group of existing and new institutional investors at a price of €6.70 per New Share, which represents a 11% discount to the closing price of June 12, 2017. The New Shares represent 5.3% of the current number of outstanding shares (pre-Transaction) and will bring the total number of shares (post-Transaction) to 14,712,770. In addition, the investors have received 746,269 5-year warrants entitling them to subscribe for 746,269 new Company shares at a warrant exercise price of €7.70 (the exercise price being subject to adjustment in case of certain corporate and dilutive events).
The New Shares will be admitted to trading on Euronext Amsterdam and Euronext Brussels following their issuance, which is expected to take place on June 15, 2017.
Kiadis Pharma will use the net proceeds of the Transaction to advance the clinical development of the Company’s ATIR products and for general corporate purposes. More… »

Kiadis Pharma announces filing of marketing authorization with the European Medicines Agency for ATIR101™ in blood cancers

Amsterdam, The Netherlands, April 26, 2017 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing innovative products to make bone marrow transplantations for patients suffering from blood cancers and inherited blood disorders safer and more effective, today announces it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for its lead product, ATIR101™. The Company is seeking marketing approval in the European Union for ATIR101™ as an adjunctive treatment in haematopoietic stem cell transplantation (HSCT) for malignant disease.
The filing is based on Kiadis Pharma’s existing clinical data and follows positive interactions with the EMA Rapporteur and Co-Rapporteur which indicated support for the filing using the Company’s single dose Phase II trial with ATIR101™ as the pivotal study. The Company submitted the application under the European Union’s centralized procedure, which permits the agency to issue a single marketing authorization that is valid across all EU countries. More… »

Kiadis Pharma announces positive regulatory update on ATIR101™ and ATIR201™

~ Regulatory approval received from the national authority in Belgium to start pivotal Phase III trial with ATIR101™ and from the national authority in Germany to start the Phase I/II trial with ATIR201™ ~

Amsterdam, The Netherlands, April 3, 2017, – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing innovative T-cell immunotherapy treatments for blood cancers and inherited blood disorders, today announces that it has obtained regulatory approval from the national authority in Belgium (the FAGG, the Federal Agency for Medicines and Health Products) to start its randomized, controlled, transatlantic Phase III clinical trial with ATIR101™ for acute leukemia (CR-AIR-009) in Belgium. In addition, the Company has received regulatory approval from the national authority in Germany (the PEI, the Paul-Ehrlich-Institute) to start its Phase I/II clinical trial with ATIR201™ for thalassemia (CR-BD-001). This follows after the previous Company announcement in February 2017 that the Phase III trial with ATIR101™ has been initiated following regulatory approval from the national authority in Canada, and from the previous Company announcement at the end of 2016 that it had initiated the Phase I/II trial with ATIR201™ after having obtained regulatory approval from the national authority in the United Kingdom.

Kiadis Pharma’s Pediatric Investigation Plan for ATIR101™ accepted by the European Medicines Agency’s Pediatric Committee

~ Paves the way for submission of a Marketing Authorization Application for ATIR101™ in Europe ~

Amsterdam, The Netherlands, March 28, 2017, – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing innovative T-cell immunotherapy treatments for blood cancers and inherited blood disorders, today announces that the Pediatric Committee (PDCO) of the European Medicines Agency (EMA) has accepted the Company’s Pediatric Investigation Plan (PIP) for ATIR101™ for the adjunctive treatment in hematopoietic stem cell transplantation (HSCT) for a malignant disease. In addition, the PDCO has agreed that the Company may defer conducting the studies defined in the PIP until after it files a Marketing Authorization Application (MAA) in Europe for the use of ATIR101™ for the treatment of blood cancers. More… »

Kiadis Pharma appoints Jan Feijen as Chief Operations Officer

Amsterdam, The Netherlands, March 20, 2017, – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing innovative T-cell immunotherapy treatments for blood cancers and inherited blood disorders, today announces the appointment of Jan Feijen as Chief Operations Officer (COO) effective from April 1, 2017.
Jan Feijen brings significant professional management skills and extensive experience in manufacturing, operations and project management to Kiadis Pharma. He is a seasoned leader who, most recently, was Vice President Manufacturing and Technical Operations Platform Lead Vaccines and Advanced Therapies at Janssen (Pharmaceutical Companies of Johnson & Johnson). Prior to that he held various executive and project lead positions at Crucell, Avebe and Gist Brocades. Jan has built and run many clinical and commercial manufacturing facilities and operations across multiple sites in Europe, the US and Asia. In his role as COO at Kiadis Pharma, Jan will be responsible for manufacturing, supply chain, QA and project management. More… »